导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 22.72% | 289/4772 |
| 近一周 | -4.49% | 5224/5464 |
| 近一月 | 0.52% | 355/5418 |
| 近一季 | 5.73% | 370/5236 |
| 近半年 | 0.88% | 1434/4930 |
| 近一年 | 19.21% | 469/4399 |
| 近两年 | 32.67% | 2160/2954 |
| 近三年 | 21.25% | 1418/2253 |
| 成立以来 | 198.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
18.19% 32/4961 |
-11.44% 4289/5312 |
- - |
- - |
| 2025 | -4.89% 3365/4813 |
-9.57% 3434/3635 |
-1.96% 3289/4076 |
7.48% 3448/4524 |
-0.18% 2400/4813 |
| 2024 | 1.53% 2003/3463 |
7.61% 235/2808 |
-0.75% 830/3014 |
4.82% 2887/3129 |
-9.31% 2918/3463 |
| 2023 | 10.42% 97/2656 |
3.28% 1224/2280 |
-5.98% 1572/2385 |
9.54% 8/2515 |
3.80% 45/2655 |
| 2022 | 16.55% 2/2207 |
21.50% 2/1919 |
9.04% 302/2016 |
4.12% 6/2113 |
-15.51% 2076/2208 |
| 2021 | 48.44% 8/1822 |
4.22% 156/1255 |
22.16% 124/1330 |
36.59% 7/1466 |
-14.64% 1631/1822 |
| 2020 | - - |
- - |
1.82% 983/1067 |
12.42% 388/1164 |
17.98% 109/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.6144 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6764 | 32.17% |
| 港股医疗 | 0.9539 | 31.90% |
| 港股医疗ETF | 1.4546 | 31.90% |
| 港股通医疗ETF工银 | 0.9639 | 31.81% |
| 港股通医疗ETF华宝 | 0.9752 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4069 | 31.06% |
| 万家中证港股通创新药ETF发起式联接C | 1.4061 | 30.98% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 嘉实中证港股通创新药指数发起式A | 0.8590 | 30.57% |
| 国泰中证煤炭ETF联接A VS. 长安沪深300非周期A(740101) |